Five-Year Changes in Weight and Diabetes Status After Bariatric Surgery for Craniopharyngioma-Related Hypothalamic Obesity: a Case-Control Study.
Bariatric surgery
Case–control study
Craniopharyngioma
Hypothalamic obesity
Type 2 diabetes
Weight loss
Journal
Obesity surgery
ISSN: 1708-0428
Titre abrégé: Obes Surg
Pays: United States
ID NLM: 9106714
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
03
02
2022
accepted:
20
04
2022
revised:
14
04
2022
pubmed:
7
5
2022
medline:
15
7
2022
entrez:
6
5
2022
Statut:
ppublish
Résumé
Craniopharyngiomas are tumors located in the hypothalamic region which leads to obesity in about 50% of cases. Long-term efficacy and safety of bariatric surgery are lacking in this peculiar population. The aim of this study is to determine the 5-year weight loss and resolution of type 2 diabetes (T2D) after bariatric surgery in patients operated on craniopharyngioma who had developed hypothalamic obesity. This is a multicenter french retrospective case-control study. Subjects with craniopharyngioma (n = 23) who underwent sleeve gastrectomy (SG) (n = 9) or Roux-en-Y gastric bypass (RYGB) (n = 14) (median age 35 years [25;43] and BMI 44.2 kg/m TWL% after 1 and 5 years was lower in the craniopharyngioma group than in the control group: 23.1 [15.4; 31.1] (23/23) vs 31.4 [23.9; 35.3] at 1 year (p = 0.008) (46/46) and 17.8 [7.1; 21.9] (23/23) vs 26.2 [18.9; 33.9] at 5 years (p = 0.003) (46/46). After RYGB, TWL% was lower in the craniopharyngioma group compared to the control group (p < 0.001) and comparable after SG both at 1 and 5 years. No difference between the two groups was observed in T2D remission rate and in early and late adverse events. No hormonal deficiency-related acute disease was reported. Bariatric surgery induced a significant weight loss in the craniopharyngioma group at 1 and 5 years, but less than in common obesity. SG may be more effective than RYGB but this remains to be demonstrated in a larger cohort.
Identifiants
pubmed: 35524022
doi: 10.1007/s11695-022-06079-9
pii: 10.1007/s11695-022-06079-9
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2321-2331Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Wang KW, et al. The effectiveness of interventions to treat hypothalamic obesity in survivors of childhood brain tumours: a systematic review. Obes Rev. 2017;18(8):899–914.
doi: 10.1111/obr.12534
van Iersel L, et al. Pathophysiology and individualized treatment of hypothalamic obesity following craniopharyngioma and other suprasellar tumors: a systematic review. Endocr Rev. 2019;40(1):193–235.
doi: 10.1210/er.2018-00017
Bretault M, et al. Management of hypothalamic obesity during transition from childhood to adulthood. Endocr Dev. 2018;33:57–67.
doi: 10.1159/000487526
Lustig RH, et al. Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2003;88(6):2586–92.
doi: 10.1210/jc.2002-030003
Mason PW, Krawiecki N, Meacham LR. The use of dextroamphetamine to treat obesity and hyperphagia in children treated for craniopharyngioma. Arch Pediatr Adolesc Med. 2002;156(9):887–92.
doi: 10.1001/archpedi.156.9.887
Lomenick JP, Buchowski MS, Shoemaker AH. A 52-week pilot study of the effects of exenatide on body weight in patients with hypothalamic obesity. Obesity (Silver Spring). 2016;24(6):1222–5.
doi: 10.1002/oby.21493
Zoicas F, et al. GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases. Eur J Endocrinol. 2013;168(5):699–706.
doi: 10.1530/EJE-12-0997
Castro-Dufourny I, Carrasco R, Pascual JM. Hypothalamic obesity after craniopharyngioma surgery: treatment with a long acting glucagon like peptide 1 derivated. Endocrinol Diabetes Nutr. 2017;64(3):182–4.
doi: 10.1016/j.endinu.2016.10.006
Thondam SK, et al. A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus. Clin Endocrinol (Oxf). 2012;77(4):635–7.
doi: 10.1111/j.1365-2265.2012.04368.x
Bretault M, Carette C, Zaharia R, et al. Liraglutide 3mg as a weight-loss strategy after failed bariatric surgery in a patient with hypothalamic obesity following craniopharyngioma. Diabetes Metab. 2020;46(6):514–5.
Arterburn DE, et al. Benefits and risks of bariatric surgery in adults: a review. JAMA. 2020;324(9):879–87.
doi: 10.1001/jama.2020.12567
Wijnen M, et al. Efficacy and safety of bariatric surgery for craniopharyngioma-related hypothalamic obesity: a matched case-control study with 2 years of follow-up. Int J Obes (Lond). 2017;41(2):210–6.
doi: 10.1038/ijo.2016.195
Bretault M, et al. Clinical review: Bariatric surgery following treatment for craniopharyngioma: a systematic review and individual-level data meta-analysis. J Clin Endocrinol Metab. 2013;98(6):2239–46.
doi: 10.1210/jc.2012-4184
Garrez I, Lapauw B, Van Nieuwenhove Y. Bariatric surgery for treatment of hypothalamic obesity after craniopharyngioma therapy: a matched case-control study. Obes Surg. 2020;30(6):2439–44.
Page-Wilson G, et al. Hypothalamic obesity in patients with craniopharyngioma: treatment approaches and the emerging role of gastric bypass surgery. Pituitary. 2012;15(1):84–92.
doi: 10.1007/s11102-011-0349-5
Rottembourg D, et al. Outcome after bariatric surgery in two adolescents with hypothalamic obesity following treatment of craniopharyngioma. J Pediatr Endocrinol Metab. 2009;22(9):867–72.
doi: 10.1515/JPEM.2009.22.9.867
Trotta M, et al. Sleeve gastrectomy leads to easy management of hormone replacement therapy and good weight loss in patients treated for craniopharyngioma. Updates Surg. 2017;69(1):95–9.
doi: 10.1007/s13304-017-0425-0
Inge TH, et al. Gastric bypass surgery for treatment of hypothalamic obesity after craniopharyngioma therapy. Nat Clin Pract Endocrinol Metab. 2007;3(8):606–9.
doi: 10.1038/ncpendmet0579
van Santen SS, Wolf P, Kremenevski N, et al. Bariatric surgery for hypothalamic obesity in craniopharyngioma patients: a retrospective, matched case-control study. J Clin Endocrinol Metab. 2021;106(11):e4734–45.
Fried M, et al. Interdisciplinary European Guidelines on metabolic and bariatric surgery. Obes Facts. 2013;6(5):449–68.
doi: 10.1159/000355480
Buse JB, et al. How do we define cure of diabetes? Diabetes Care. 2009;32(11):2133–5.
doi: 10.2337/dc09-9036
Pickering L, et al. Sleep-wake and melatonin pattern in craniopharyngioma patients. Eur J Endocrinol. 2014;170(6):873–84.
doi: 10.1530/EJE-13-1025
Muller HL. Increased daytime sleepiness in patients with childhood craniopharyngioma and hypothalamic tumor involvement: review of the literature and perspectives. Int J Endocrinol. 2010;2010: 519607.
doi: 10.1155/2010/519607
Jayaraj P, et al. Does beta-catenin have a role in pathogenesis of sebaceous cell carcinoma of the eyelid? Br J Ophthalmol. 2011;95(2):284–7.
doi: 10.1136/bjo.2009.177204
Weismann D, et al. Bariatric surgery for morbid obesity in craniopharyngioma. Clin Endocrinol (Oxf). 2013;78(3):385–90.
doi: 10.1111/j.1365-2265.2012.04409.x
Papamargaritis D, le Roux CW. Do gut hormones contribute to weight loss and glycaemic outcomes after bariatric surgery? Nutrients. 2021;13(3):762.
doi: 10.3390/nu13030762
Castellana M, et al. Roux-en-Y gastric bypass vs sleeve gastrectomy for remission of type 2 diabetes. J Clin Endocrinol Metab. 2021;106(3):922–33.
doi: 10.1210/clinem/dgaa737
Wijnen M, et al. Excess morbidity and mortality in patients with craniopharyngioma: a hospital-based retrospective cohort study. Eur J Endocrinol. 2018;178(1):93–102.
doi: 10.1530/EJE-17-0707
Trivin C, et al. Childhood craniopharyngioma: greater hypothalamic involvement before surgery is associated with higher homeostasis model insulin resistance index. BMC Pediatr. 2009;9:24.
doi: 10.1186/1471-2431-9-24
Arterburn D, et al. Comparative effectiveness and safety of bariatric procedures for weight loss: a PCORnet cohort study. Ann Intern Med. 2018;169(11):741–50.
doi: 10.7326/M17-2786
Brethauer SA, et al. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg. 2013;258(4):628–36. discussion 636-7.
doi: 10.1097/SLA.0b013e3182a5034b
Debedat J, et al. Long-term relapse of type 2 diabetes after Roux-en-Y gastric bypass: prediction and clinical relevance. Diabetes Care. 2018;41(10):2086–95.
doi: 10.2337/dc18-0567